Diabetes and cardiovascular disease are two faces of the same problem, and treating them separately fails patients. Clinicians who manage diabetic patients see the pattern constantly: heart failure hospitalizations, silent coronary disease, and cardiorenal decline that outpaces textbook expectations built on outdated single-organ models.

Without a unified framework linking hyperglycemic vascular injury to myocardial dysfunction, treatment decisions lag behind the evidence. Patients on outdated glycemic-only strategies miss the cardioprotective benefit now proven for SGLT2 inhibitors and GLP-1 receptor agonists, and clinicians without a clear mechanistic map struggle to explain why these agents changed practice.

This 2026 edition delivers the complete diabeto-cardiology framework in one reference.

• Molecular mechanisms of hyperglycemia-induced vascular injury and diabetic cardiomyopathy

• Heart failure with preserved and reduced ejection fraction in the diabetic patient

• Cardiorenal syndrome and the KDIGO risk framework

• Full outcome-trial coverage of SGLT2 inhibitors and GLP-1 receptor agonists, including EMPA-REG OUTCOME, DAPA-HF, LEADER, and SELECT

• Revascularization, antiplatelet strategy, and perioperative management in diabetic coronary disease

Every chapter includes clinical pearls, case vignettes, drug-dosing snapshots, and red-flag alerts built for point-of-care use. Two clinical illustrations per chapter clarify mechanism and anatomy across all 25 chapters.

A companion video course of more than 100 curated lectures, accessible by scanning the QR code included in this edition, extends every chapter with expert-led teaching.

Written for cardiologists, endocrinologists, nephrologists, internists, and advanced practice clinicians who need one current, clinically actionable reference for the diabetes-cardiovascular interface.